Streetbeat News

Products Services

CMMB

Chemomab Therapeutics reported positive topline results from the Phase 2 SPRING trial of CM-101 for primary sclerosing cholangitis, achieving its primary endpoint with demonstrated anti-fibrotic, anti-inflammatory, and anti-cholestatic effects.

Portfolio Pulse from Benzinga Newsdesk

July 25, 2024 | 11:45 am

META

Mark Zuckerberg, CEO of Meta Platforms Inc. (NASDAQ:META), dismissed rumors that his unusual tan is related to a new augmented-reality device called 'Orion.' Speculation arose after an interview where Zuckerberg appeared with a distinctive tan, but he clarified it was just from wearing Ray-Ban sunglasses. The news also highlighted Meta's AI capabilities and Zuckerberg's criticism of Apple.

Portfolio Pulse from Ananya Gairola

July 25, 2024 | 11:45 am

ASTS

AST SpaceMobile has completed its first five commercial satellites, named Bluebirds. Each satellite has a communications array of 693 square feet and is ready for shipment to Cape Canaveral in early August, with a launch window in September.

Portfolio Pulse from Benzinga Newsdesk

July 25, 2024 | 11:42 am

AAPL

Apple Inc. (NASDAQ:AAPL) has dropped from third to sixth place in the Chinese smartphone market, with its market share falling to 14% in Q2 2024. Meanwhile, Huawei has seen a 41% increase in shipments, driven by the launch of its Pura 70 series. Apple faces intense competition and has increased discounting efforts to regain market share.

Portfolio Pulse from Rounak Jain

July 25, 2024 | 11:42 am

IMNM

Nectin Therapeutics has entered into a global, exclusive license agreement with Immunome, granting Immunome exclusive rights to a panel of antibodies targeting an undisclosed target. Immunome will handle research, development, manufacturing, and commercialization, while Nectin will receive an upfront payment, milestones, and royalties.

Portfolio Pulse from Benzinga Newsdesk

July 25, 2024 | 11:41 am

BFRG

BullFrog AI has announced significant advancements in its collaboration with the Lieber Institute for Brain Development, focusing on molecular pathways associated with bipolar disorder. This progress enables the identification of new candidate drug targets.

Portfolio Pulse from Benzinga Newsdesk

July 25, 2024 | 11:40 am

ME

23andMe, in collaboration with 20 lung cancer advocacy organizations, announced a new study to advance research in lung cancer genetics. The study aims to improve detection, risk reduction, and care for lung cancer patients.

Portfolio Pulse from Benzinga Newsdesk

July 25, 2024 | 11:36 am

CKPT

Checkpoint Therapeutics announced that the FDA has accepted for review its resubmission of the Biologics License Application for Cosibelimab, an anti-PD-L1 antibody for treating metastatic or locally advanced cutaneous squamous cell carcinoma. The FDA has set a PDUFA goal date of December 28, 2024.

Portfolio Pulse from Benzinga Newsdesk

July 25, 2024 | 11:33 am

QUIK

SensiML, a subsidiary of QuickLogic, has released a new generative AI feature for its Data Studio application, enhancing dataset management for IoT edge devices. This feature allows developers to create hyper-realistic synthetic speech datasets for building AI models optimized for low-power microcontrollers.

Portfolio Pulse from Benzinga Newsdesk

July 25, 2024 | 11:31 am

SHYF

Shyft Group has acquired Independent Truck Upfitters, a service body and work truck upfitter based in the Midwest. The acquisition aligns with Shyft's growth strategy focused on specialty vehicles infrastructure. Financial terms were not disclosed.

Portfolio Pulse from Benzinga Newsdesk

July 25, 2024 | 11:30 am